Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis
Alimentary Pharmacology & Therapeutics2016Vol. 43(12), pp. 1293–1299
Citations Over TimeTop 10% of 2016 papers
Bella Ungar, Yoav Mazor, Roni Weisshof, Henit Yanai, Yulia Ron, Idan Goren, Amir Waizbard, Miri Yavzori, Ella Fudim, Orit Picard, Ronen Loebstein, Uri Kopylov, Iris Dotan, Yehuda Chowers, Rami Eliakim, Shomron Ben‐Horin
Abstract
Infliximab trough levels at day 14 were lower in patients with acute severe UC compared to moderately severe UC, possibly due to a higher inflammatory burden and/or increased drug clearance. However, drug levels at day 14 were not lower among nonresponders compared with responders. Controlled trials are warranted to examine whether an a-priori-intensified infliximab induction protocol will lead to an improved outcome in acute severe UC.
Related Papers
- → Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease(2011)111 cited
- → Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study(2011)41 cited
- → Does Smoking Reduce Infliximab’s Effectiveness against Crohn’s Disease?(2009)22 cited
- [Management of failure of infliximab in inflammatory bowel disease].(2011)
- Determination of plasma P-selection in patients with ulcerative colitis and their clinical significance(2004)